Related Experiment Videos
Precision, prevention and progress: charting two decades of change in gynaecological oncology-a narrative review
Sabina Ioana Nistor1, Ruyu Shao2, Jacopo Conforti1,3
1Department of Gynaecological Oncology, Churchill Hospital, Oxford University Hospitals National Health Service (NHS) Foundation Trust, Oxford, UK.
Background And Objective:
The field of Gynaecological Oncology (GO) has undergone a paradigm shift over recent decades, shaped by advancements in prevention, molecular therapeutics, and surgical innovation. We explore how the management of gynaecological malignancies has transformed in the past 25 years.
Methods:
A structured narrative review of landmark publications and guideline updates published between 2000 and 2025 was undertaken. Key developments in the management of cervical, ovarian, endometrial, vulvar, and vaginal cancers were critically analysed, with particular focus on prevention strategies, surgical evolution, and integration of targeted and immune therapies.
Key Content And Findings:
In cervical cancer, population-level human papillomavirus (HPV) vaccination has dramatically reduced incidence, while the LACC and SHAPE trials prompted a return to open and less radical surgery, respectively. Sentinel node biopsy is supplanting systematic lymphadenectomy, and combined chemoradiotherapy (CRT) with immunotherapy is improving survival in locally advanced disease. For ovarian cancer, optimal cytoreduction remains key, with TRUST highlighting surgical quality, while heated intraperitoneal chemotherapy (HIPEC) and poly-ADP ribose polymerase (PARP) inhibitors-alone or combined with immunotherapy-extend progression-free survival (PFS). Endometrial cancer management is now driven by molecular classification [The Cancer Genome Atlas (TCGA)/Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE)], with immunotherapy and targeted therapy transforming outcomes. In vulvar and vaginal cancers, GROINSS-V (Groin Sentinel Node Trial in Vulvar Cancer) and related studies underpin de-escalated and minimally invasive nodal surgery, while immunotherapy emerges for advanced disease.
Conclusions:
Modern GO is defined by prevention, precision, and personalisation. The contemporary Gynaecological Oncologist now integrates molecular insight, function-preserving surgery, and multidisciplinary collaboration to deliver optimised, patient-centred care.
Related Concept Videos
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Cancer Survival Analysis
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...